EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends

Cassandra Catacalos-Goad, Charlotte Johnstone, Valery Z Grdzelishvili

Current Oncology · 2025

DOI: 10.3390/curroncol32110627 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2025. Verfasst von Cassandra Catacalos-Goad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms, Vesiculovirus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic virotherapy has emerged as a promising and innovative approach to cancer treatment, leveraging viruses that selectively replicate in tumor cells and cause their destruction (oncolysis), while simultaneously stimulating anti-tumor immune responses. Vesicular stomatitis virus (VSV), a prototypic rhabdovirus, is among the most versatile oncolytic virus platforms due to its favorable biological characteristics, including rapid replication and cell lysis, lack of pre-existing immunity in humans, and amenability to genetic engineering. Over the past decade, significant progress has been made in VSV-based oncolytic virotherapy. This review presents a comprehensive update on developments since our last review, emphasizing improvements in VSV safety, oncoselectivity, tumor-specific replication, direct oncolysis, and induction of antitumor immunity. By integrating recent applied discoveries with foundational knowledge, this review aims to guide ongoing efforts to advance VSV-based oncolytic virotherapy toward broader clinical translation and improved cancer patient outcomes. Additionally, we provide an overview of three closely related rhabdoviruses (Maraba, Morreton, and Jurona viruses) as emerging oncolytic platforms currently under preclinical and clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyOncolytic VirusesNeoplasmsVesiculovirusHumansAnimals

Stichwörter der Autor:innen

Jurona virusMaraba virusMorreton virusVSVcancer therapyoncolytic virotherapyrhabdovirusvesicular stomatitis virus

Autor:innen und Institutionen

  • Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute, National Institutes of Health

Zitieren

APA

Catacalos-Goad, C., Johnstone, C., & Grdzelishvili, V. Z. (2025). Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends. Current Oncology. https://doi.org/10.3390/curroncol32110627

Vancouver

Catacalos-Goad C, Johnstone C, Grdzelishvili VZ. Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends. Current Oncology. 2025. doi:10.3390/curroncol32110627

BibTeX
@article{CatacalosGoad2025,
  author = {Catacalos-Goad, Cassandra and Johnstone, Charlotte and Grdzelishvili, Valery Z},
  title = {Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32110627}
}
Kostenlos starten →